Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc. (ORIC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Oric is a clinical-stage biopharmaceutical company focused on overcoming resistance in cancer. The company operates with a fully integrated discovery and development team targeting hormone-dependent cancers, precision oncology, and key tumor dependencies. As of December 31, 2024, the company had 115 full-time employees, with 86 engaged in research and development.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(127.8) million | $(100.7) million |
| Accumulated Deficit | $(562.8) million | $(434.9) million |
| Research & Development Expenses | $114.1 million | $85.2 million |
| General & Administrative Expenses | $28.8 million | $25.6 million |
| Cash, Cash Equivalents, and Investments | $256.0 million | $208.2 million |
| Net Cash Used in Operating Activities | $(112.7) million | $(85.7) million |
| Net Cash Provided by Financing Activities | $126.5 million | $85.7 million |
Note: The company has no revenue and operates at a loss. Margins are not applicable.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $32.1 million (29%) to $142.9 million in 2024. This was driven primarily by a $28.9 million increase in R&D expenses.
- R&D Spend Drivers: External R&D costs increased by $22.4 million due to the advancement of lead candidates ORIC-114 and ORIC-944. Internal personnel costs increased by $6.5 million, including $2.3 million in additional stock-based compensation.
- Capital Raise: In January 2024, the company completed a private placement of 12.5 million shares at $10.00 per share, generating gross proceeds of $125.0 million. This significantly bolstered liquidity compared to the prior year.
- Net Loss Expansion: Net loss increased by $27.2 million year-over-year, reflecting the higher burn rate associated with advancing clinical trials.
Guidance, Outlook, and Risks
Outlook and Clinical Progress
- Liquidity: Management believes existing cash, cash equivalents, and investments ($256.0 million) are sufficient to fund operations into late 2026.
- ORIC-114 (EGFR/HER2 Inhibitor):
- Phase 1b dose expansion cohorts initiated for second-line NSCLC patients.
- Provisional recommended Phase 2 doses (RP2D) selected at 80 mg and 120 mg daily.
- New collaboration with Johnson & Johnson to evaluate ORIC-114 in combination with amivantamab for first-line treatment; Phase 1b trial initiated in Q1 2025.
- Updated Phase 1b data expected in H1 2025 (2L EGFR/HER2) and H2 2025 (2L+ EGFR atypical).
- ORIC-944 (PRC2 Inhibitor):
- Phase 1b monotherapy data reported in Jan 2024 showing favorable safety and target engagement.
- Combination trials with apalutamide (Johnson & Johnson) and darolutamide (Bayer) initiated in H1 2024.
- Early combination data with apalutamide reported in Jan 2025 showing deep PSA decreases.
- Updated combination data expected in Q4 2025 or H1 2026.
Risks and Contingencies
- Need for Additional Capital: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding to complete development and commercialization.
- Clinical Trial Risks: Success depends on the safety and efficacy of product candidates in clinical trials, which are inherently uncertain. Failure to demonstrate efficacy or safety could halt development.
- Regulatory Approval: No products are approved for commercial sale. Regulatory approval is not guaranteed and may be delayed or denied.
- Third-Party Dependence: The company relies on third parties for manufacturing and clinical trial conduct. Supply chain disruptions or manufacturer failures could delay trials.
- Legal Proceedings: The company's Chief Business Officer was found liable for insider trading in a matter unrelated to Oric (involving a prior employer) in April 2024. The officer has appealed the decision.
Key Facts for Investor Verification
- Cash Runway: Verify the company's projection that $256.0 million in liquid assets will sustain operations into late 2026, given the current burn rate of approximately $113 million annually.
- Clinical Milestones: Monitor the upcoming data readouts for ORIC-114 (H1/H2 2025) and ORIC-944 (Q4 2025/H1 2026) to assess the probability of advancing to Phase 2.
- Collaboration Terms: Review the specific terms of the new Johnson & Johnson and Bayer collaborations to understand potential future revenue streams or milestone payments.
- Capital Markets: Assess the company's ability to raise additional capital if clinical results are positive but require significant further investment, or if the market environment deteriorates.
- Legal Status: Track the status of the appeal regarding the Chief Business Officer's insider trading conviction to evaluate potential reputational or governance risks.